Chandler O'LEary
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chandler O'LEary has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Mei Liu
Department of Biochemistry and Biophysics, Texas A&M University, College Station, Texas, USA
5 shared publications - Ry Young
Department of Biochemistry and Biophysics, Texas A&M University, College Station, Texas, USA
4 shared publications Jason J. Gill
Center for Phage Technology, Texas A&M University, College Station, Texas, USA
3 shared publications- Jesse Cahill
Environmental Systems Biology, Sandia National Laboratories, Albuquerque NM, USA
3 shared publications - Shahman Shahab
The University of Texas Medical Branch, John Sealy School of Medicine, Galveston, Texas, USA
3 shared publications Aneesha Kulkarni
Center of Phage Technology, Department of Biochemistry and Biophysics, Texas A&M University, College Station, Texas, USA
2 shared publications
Latest Publications
- Open Access
- 2 October 2026
- Published by Elsevier in SSRN Electronic Journal
Clinical Outcomes Associated With Glucagon-Like Peptide-1 Receptor Agonist Use Following Recent Hospitalization for Heart Failure With Preserved Ejection Fraction
BackgroundGlucagon-like peptide-1 receptor agonists improve symptoms and functional status in obesity-related heart failure with preserved ejection fraction, but outcomes after recent hospitalization remain uncertain. This study aims to evaluate associations between glucagon-like peptide-1 receptor agonist use and outcomes after hospitalization for acute heart failure with preserved ejection fraction.MethodsWe conducted a retrospective cohort study using the TriNetX Collaborative Network in the United States. Women and men with heart failure with preserved ejection fraction and overweight or obesity were included after first-hospitalization for acute or acute-on-chronic diastolic heart failure. Propensity score matching balanced demographics, comorbidities, and cardiovascular medications. Outcomes were assessed from 90 days after index through 1 and 5 years.ResultsAfter matching, each cohort included 893 patients at 1 year and 663 at 5 years. Glucagon-like peptide-1 receptor agonists use was not associated with lower 1-year heart failure with preserved ejection fraction hospitalization (hazard ratio 0.99, 95% confidence interval 0.78 to 1.25; p = 0.93) or all-cause hospitalization (hazard ratio 0.92, 95% confidence interval 0.75 to 1.11; p = 0.37). Mortality was numerically lower at 1 year (hazard ratio 0.68, 95% confidence interval 0.46 to 1.02; p = 0.058) and lower at 5 years (hazard ratio 0.72, 95% confidence interval 0.53 to 0.97; p = 0.032).ConclusionsUse after hospitalization was not associated with fewer recurrent exacerbations or hospitalizations but was associated with lower long-term mortality. The finding is hypothesis-generating.
- 2 October 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessClinical Outcomes Associated With Glucagon-Like Peptide-1 Receptor Agonist Use Following Recent Hospitalization for Heart Failure With Preserved Ejection Fraction
BackgroundGlucagon-like peptide-1 receptor agonists improve symptoms and functional status in obesity-related heart failure with preserved ejection fraction, but outcomes after recent hospitalization remain uncertain. This study aims to evaluate associations between glucagon-like peptide-1 receptor agonist use and outcomes after hospitalization for acute heart failure with preserved ejection fraction.MethodsWe conducted a retrospective cohort study using the TriNetX Collaborative Network in the United States. Women and men with heart failure with preserved ejection fraction and overweight or obesity were included after first-hospitalization for acute or acute-on-chronic diastolic heart failure. Propensity score matching balanced demographics, comorbidities, and cardiovascular medications. Outcomes were assessed from 90 days after index through 1 and 5 years.ResultsAfter matching, each cohort included 893 patients at 1 year and 663 at 5 years. Glucagon-like peptide-1 receptor agonists use was not associated with lower 1-year heart failure with preserved ejection fraction hospitalization (hazard ratio 0.99, 95% confidence interval 0.78 to 1.25; p = 0.93) or all-cause hospitalization (hazard ratio 0.92, 95% confidence interval 0.75 to 1.11; p = 0.37). Mortality was numerically lower at 1 year (hazard ratio 0.68, 95% confidence interval 0.46 to 1.02; p = 0.058) and lower at 5 years (hazard ratio 0.72, 95% confidence interval 0.53 to 0.97; p = 0.032).ConclusionsUse after hospitalization was not associated with fewer recurrent exacerbations or hospitalizations but was associated with lower long-term mortality. The finding is hypothesis-generating.
- Open Access
- 16 September 2026
- Published by Elsevier in JACC: Case Reports
- Vol. 31 (37)
Radiation Dose Reduction in Coronary Computed Tomography Angiography
- 16 September 2026
- Published by Elsevier in JACC: Case Reports
- Vol. 31 (37)
Open AccessRadiation Dose Reduction in Coronary Computed Tomography Angiography
- Open Access
- 7 October 2025
- Published by Elsevier in JACC: Case Reports
- Vol. 30 (36) , 105656
Improving Patient Access and Scanning Efficiency in Cardiovascular Magnetic Resonance
- 7 October 2025
- Published by Elsevier in JACC: Case Reports
- Vol. 30 (36) , 105656
Open AccessImproving Patient Access and Scanning Efficiency in Cardiovascular Magnetic Resonance
- Open Access
- 1 June 2025
- Published by SAGE Publications in Clinical Medicine Insights: Cardiology
- Vol. 19
Coronary Revascularization in the Era of TAVR: Timing, Strategy, and Outcomes
Background: Coronary artery disease (CAD) is prevalent among patients undergoing transcatheter aortic valve replacement (TAVR), complicating clinical decision-making regarding optimal timing of percutaneous coronary intervention (PCI). Despite widespread clinical experience, there is ongoing controversy and limited consensus regarding when PCI, before, during, or after TAVR, offers the best risk-benefit balance. Objective: To synthesize and critically evaluate the current evidence on different PCI timing strategies in patients undergoing TAVR and to identify areas of uncertainty and clinical complexity. Review: Randomized trials, including ACTIVATION and NOTION-3, have yielded mixed findings, highlighting a modest reduction in ischemic events with pre-TAVR PCI but increased procedural bleeding risks. Observational registries (REVASC-TAVI and the National Readmissions Database) have similarly shown that pre- and peri-TAVR PCI strategies carry heightened risks of complications without clear long-term mortality benefits. Recent meta-analyses reinforce these findings, indicating that no PCI timing strategy conclusively outperforms others in reducing long-term mortality. Key considerations such as anatomical complexity, frailty, bleeding risk, and valve type significantly influence optimal PCI timing. Conclusion: Current evidence supports a personalized, patient-centered approach to PCI timing in TAVR candidates, emphasizing careful consideration of individual anatomical and clinical factors rather than a standardized timing protocol. Further research exploring advanced risk stratification, imaging modalities, and long-term clinical outcomes is essential to refine current guidelines and practice.
- 1 June 2025
- Published by SAGE Publications in Clinical Medicine Insights: Cardiology
- Vol. 19
Open AccessCoronary Revascularization in the Era of TAVR: Timing, Strategy, and Outcomes
Background: Coronary artery disease (CAD) is prevalent among patients undergoing transcatheter aortic valve replacement (TAVR), complicating clinical decision-making regarding optimal timing of percutaneous coronary intervention (PCI). Despite widespread clinical experience, there is ongoing controversy and limited consensus regarding when PCI, before, during, or after TAVR, offers the best risk-benefit balance. Objective: To synthesize and critically evaluate the current evidence on different PCI timing strategies in patients undergoing TAVR and to identify areas of uncertainty and clinical complexity. Review: Randomized trials, including ACTIVATION and NOTION-3, have yielded mixed findings, highlighting a modest reduction in ischemic events with pre-TAVR PCI but increased procedural bleeding risks. Observational registries (REVASC-TAVI and the National Readmissions Database) have similarly shown that pre- and peri-TAVR PCI strategies carry heightened risks of complications without clear long-term mortality benefits. Recent meta-analyses reinforce these findings, indicating that no PCI timing strategy conclusively outperforms others in reducing long-term mortality. Key considerations such as anatomical complexity, frailty, bleeding risk, and valve type significantly influence optimal PCI timing. Conclusion: Current evidence supports a personalized, patient-centered approach to PCI timing in TAVR candidates, emphasizing careful consideration of individual anatomical and clinical factors rather than a standardized timing protocol. Further research exploring advanced risk stratification, imaging modalities, and long-term clinical outcomes is essential to refine current guidelines and practice.
- Open Access
Spatial and temporal control of lysis by the lambda holin
The infection cycle of phage λ terminates in lysis mediated by three types of lysis proteins, each disrupting a layer in the bacterial envelope: the S105 holin, the R endolysin, and the Rz/Rz1 spanin complex targeting the inner membrane (IM), cell wall or peptidoglycan (PG), and the outer membrane (OM), respectively. Video microscopy has shown that in most infections lysis occurs as a sudden, explosive event at a cell pole, such that the initial product is a less refractile ghost that retains rod-shaped morphology. Here, we investigate the molecular basis of polar lysis using time lapse fluorescence microscopy. The results indicate that the holin determines the morphology of lysis by suddenly forming two-dimensional rafts at the poles about 100 seconds prior to lysis. Given the physiological and biochemical similarities between the lambda holin and other class I holins, dynamic redistribution and sudden concentration may be common features of holins, probably reflecting the fitness advantage of all-or-nothing lysis regulation.
Open AccessSpatial and temporal control of lysis by the lambda holin
The infection cycle of phage λ terminates in lysis mediated by three types of lysis proteins, each disrupting a layer in the bacterial envelope: the S105 holin, the R endolysin, and the Rz/Rz1 spanin complex targeting the inner membrane (IM), cell wall or peptidoglycan (PG), and the outer membrane (OM), respectively. Video microscopy has shown that in most infections lysis occurs as a sudden, explosive event at a cell pole, such that the initial product is a less refractile ghost that retains rod-shaped morphology. Here, we investigate the molecular basis of polar lysis using time lapse fluorescence microscopy. The results indicate that the holin determines the morphology of lysis by suddenly forming two-dimensional rafts at the poles about 100 seconds prior to lysis. Given the physiological and biochemical similarities between the lambda holin and other class I holins, dynamic redistribution and sudden concentration may be common features of holins, probably reflecting the fitness advantage of all-or-nothing lysis regulation.
- Open Access
- 28 June 2021
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 12, 657524
Differential Bacteriophage Efficacy in Controlling Salmonella in Cattle Hide and Soil Models
AsymptomaticSalmonellacarriage in beef cattle is a food safety concern and the beef feedlot environment and cattle hides are reservoirs of this pathogen. Bacteriophages present an attractive non-antibiotic strategy for control ofSalmonellain beef. In this study, four diverse and genetically unrelatedSalmonellaphages, Sergei, Season12, Sw2, and Munch, were characterized and tested alone and in combination for their ability to controlSalmonellain cattle hide and soil systems, which are relevant models forSalmonellacontrol in beef production. Phage Sergei is a member of the genusSashavirus, phage Season12 was identified as a member of theChivirusgenus, Sw2 was identified as a member of the T5-likeEpseptimavirusgenus, and Munch was found to be a novel “jumbo” myovirus. Observed pathogen reductions in the model systems ranged from 0.50 to 1.75 log10CFU/cm2in hides and from 0.53 to 1.38 log10CFU/g in soil, with phages Sergei and Sw2 producing greater reductions (∼1 log10CFU/cm2or CFU/g) than Season12 and Munch. These findings are in accordance with previous observations of phage virulence, suggesting the simple ability of a phage to form plaques on a bacterial strain is not a strong indicator of antimicrobial activity, but performance in liquid culture assays provides a better predictor. The antimicrobial efficacies of phage treatments were found to be phage-specific across model systems, implying that a phage capable of achieving bacterial reduction in one model is more likely to perform well in another. Phage combinations did not produce significantly greater efficacy than single phages even after 24 h in the soil model, and phage-insensitive colonies were not isolated from treated samples, suggesting that the emergence of phage resistance was not a major factor limiting efficacy in this system.
- 28 June 2021
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 12, 657524
Open AccessDifferential Bacteriophage Efficacy in Controlling Salmonella in Cattle Hide and Soil Models
AsymptomaticSalmonellacarriage in beef cattle is a food safety concern and the beef feedlot environment and cattle hides are reservoirs of this pathogen. Bacteriophages present an attractive non-antibiotic strategy for control ofSalmonellain beef. In this study, four diverse and genetically unrelatedSalmonellaphages, Sergei, Season12, Sw2, and Munch, were characterized and tested alone and in combination for their ability to controlSalmonellain cattle hide and soil systems, which are relevant models forSalmonellacontrol in beef production. Phage Sergei is a member of the genusSashavirus, phage Season12 was identified as a member of theChivirusgenus, Sw2 was identified as a member of the T5-likeEpseptimavirusgenus, and Munch was found to be a novel “jumbo” myovirus. Observed pathogen reductions in the model systems ranged from 0.50 to 1.75 log10CFU/cm2in hides and from 0.53 to 1.38 log10CFU/g in soil, with phages Sergei and Sw2 producing greater reductions (∼1 log10CFU/cm2or CFU/g) than Season12 and Munch. These findings are in accordance with previous observations of phage virulence, suggesting the simple ability of a phage to form plaques on a bacterial strain is not a strong indicator of antimicrobial activity, but performance in liquid culture assays provides a better predictor. The antimicrobial efficacies of phage treatments were found to be phage-specific across model systems, implying that a phage capable of achieving bacterial reduction in one model is more likely to perform well in another. Phage combinations did not produce significantly greater efficacy than single phages even after 24 h in the soil model, and phage-insensitive colonies were not isolated from treated samples, suggesting that the emergence of phage resistance was not a major factor limiting efficacy in this system.
- Open Access
- 26 November 2020
- Published by Springer Nature in Nature Communications
- Vol. 11 (1) , 1-11
Rapid de novo evolution of lysis genes in single-stranded RNA phages
Leviviruses are bacteriophages with small single-stranded RNA genomes consisting of 3-4 genes, one of which (sgl) encodes a protein that induces the host to undergo autolysis and liberate progeny virions. Recent meta-transcriptomic studies have uncovered thousands of leviviral genomes, but most of these lack an annotated sgl, mainly due to the small size, lack of sequence similarity, and embedded nature of these genes. Here, we identify sgl genes in 244 leviviral genomes and functionally characterize them in Escherichia coli. We show that leviviruses readily evolve sgl genes and sometimes have more than one per genome. Moreover, these genes share little to no similarity with each other or to previously known sgl genes, thus representing a rich source for potential protein antibiotics.
- 26 November 2020
- Published by Springer Nature in Nature Communications
- Vol. 11 (1) , 1-11
Open AccessRapid de novo evolution of lysis genes in single-stranded RNA phages
Leviviruses are bacteriophages with small single-stranded RNA genomes consisting of 3-4 genes, one of which (sgl) encodes a protein that induces the host to undergo autolysis and liberate progeny virions. Recent meta-transcriptomic studies have uncovered thousands of leviviral genomes, but most of these lack an annotated sgl, mainly due to the small size, lack of sequence similarity, and embedded nature of these genes. Here, we identify sgl genes in 244 leviviral genomes and functionally characterize them in Escherichia coli. We show that leviviruses readily evolve sgl genes and sometimes have more than one per genome. Moreover, these genes share little to no similarity with each other or to previously known sgl genes, thus representing a rich source for potential protein antibiotics.
- Open Access
- 17 October 2019
- Published by American Society for Microbiology in Microbiology Resource Announcements
- Vol. 8 (42) , e01153-19
Complete Genome Sequence of Citrobacter freundii Myophage Maleficent
Citrobacter freundii, a member of theEnterobacteriaceaefamily, has been linked to opportunistic infections in neonates and immunocompromised adults. Here, we report the complete genome sequence of a T4-like myophage, Maleficent, which infectsC. freundii.
- 17 October 2019
- Published by American Society for Microbiology in Microbiology Resource Announcements
- Vol. 8 (42) , e01153-19
Open AccessComplete Genome Sequence of Citrobacter freundii Myophage Maleficent
Citrobacter freundii, a member of theEnterobacteriaceaefamily, has been linked to opportunistic infections in neonates and immunocompromised adults. Here, we report the complete genome sequence of a T4-like myophage, Maleficent, which infectsC. freundii.
- Open Access
- 25 April 2019
- Published by American Society for Microbiology in Microbiology Resource Announcements
- Vol. 8 (17) , e00255-19
Complete Genome Sequence of Salmonella enterica Serovar Newport Myophage Melville
Multiple antimicrobial-resistant strains ofSalmonella entericaserovar Newport have been recorded. Study on phages infectingS.Newport may provide new therapeutics or diagnostics for this pathogen.
- 25 April 2019
- Published by American Society for Microbiology in Microbiology Resource Announcements
- Vol. 8 (17) , e00255-19
Open AccessComplete Genome Sequence of Salmonella enterica Serovar Newport Myophage Melville
Multiple antimicrobial-resistant strains ofSalmonella entericaserovar Newport have been recorded. Study on phages infectingS.Newport may provide new therapeutics or diagnostics for this pathogen.
- Open Access
- 25 April 2019
- Published by American Society for Microbiology in Microbiology Resource Announcements
- Vol. 8 (17) , e00187-19
Complete Genome Sequence of Salmonella enterica Serovar Enteritidis Myophage Mooltan
Salmonella entericaserovar Enteritidis is a Gram-negative bacterium and one of the most common foodborne pathogens. Biocontrol using bacteriophage in food products or animals is one possible means by which pathogenic salmonellosis infection could be inhibited.
- 25 April 2019
- Published by American Society for Microbiology in Microbiology Resource Announcements
- Vol. 8 (17) , e00187-19
Open AccessComplete Genome Sequence of Salmonella enterica Serovar Enteritidis Myophage Mooltan
Salmonella entericaserovar Enteritidis is a Gram-negative bacterium and one of the most common foodborne pathogens. Biocontrol using bacteriophage in food products or animals is one possible means by which pathogenic salmonellosis infection could be inhibited.